Feasibility and acceptability of immunotherapy in antibody positive patients
The SINAPPS1 study aimed at determining which treatment is considered by participants as the most acceptable and least invasive, while still being effective in removing pathogenic antibodies.
These findings have been applied in designing the SINAPPS2 study.
SINAPPS1 completed recruitment on July 2017.
This study was funded by the Stanley Medical Research Institute.
A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis
The SINAPP2 trial will investigate the use of Intravenous Immunoglobulin (IVIG) and Rituximab as a treatment for symptoms of psychosis in antibody positive patients. The study will take place in 8 different sites across England to make it accessible to as many participants as possible.
Recruitment began in July 2017 and the study will run until 2021.
Click here for more information.
This trial is funded by the Medical Research Council.
SINAPPS1 was a feasibility study, involving a very small number of patients. In this study we aimed to identify the most acceptable treatment to eliminate pathogenic antibodies.
SINAPPS2 is a study involving participants from all across England, testing the efficacy and safety of immunotherapy in treating symptoms of psychosis in patients with pathogenic antibodies.
You can keep up to date with our studies by following us on social media